Success Metrics

Clinical Success Rate
25.0%

Based on 1 completed trials

Completion Rate
25%(1/4)
Active Trials
2(20%)
Results Posted
0%(0 trials)
Terminated
3(30%)

Phase Distribution

Ph phase_1
10
100%

Phase Distribution

10

Early Stage

0

Mid Stage

0

Late Stage

Phase Distribution10 total trials
Phase 1Safety & dosage
10(100.0%)

Highest Phase Reached

Phase 1

Trial Status & Enrollment

Completion Rate

16.7%

1 of 6 finished

Non-Completion Rate

83.3%

5 ended early

Currently Active

2

trials recruiting

Total Trials

10

all time

Status Distribution
Active(3)
Completed(1)
Terminated(5)
Other(1)

Detailed Status

Terminated3
Withdrawn2
Active, not recruiting2
Not yet recruiting1
unknown1
Completed1

Development Timeline

Analytics

Development Status

Total Trials
10
Active
2
Success Rate
25.0%
Most Advanced
Phase 1

Trials by Phase

Phase 110 (100.0%)

Trials by Status

withdrawn220%
not_yet_recruiting110%
unknown110%
active_not_recruiting220%
completed110%
terminated330%

Recent Activity

2 active trials
Showing 5 of 10
terminatedphase_1

Dose Finding Study of TNO155 in Adult Patients With Advanced Solid Tumors

NCT03114319
not_yet_recruitingphase_1

Rollover Study for Participants Who Have Been Treated With and Are Continuing to Benefit From Opnurasib as a Single Agent or in Combination With Other Study Treatments

NCT07468071
active_not_recruitingphase_1

Study of JDQ443 in Patients With Advanced Solid Tumors Harboring the KRAS G12C Mutation

NCT04699188
terminatedphase_1

A Study of Select Drug Combinations in Adult Patients With Advanced/Metastatic BRAF V600 Colorectal Cancer

NCT04294160
active_not_recruitingphase_1

Sotorasib Activity in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation (CodeBreak 101)

NCT04185883
View all 10 trials

Clinical Trials (10)

Showing 10 of 10 trials
NCT03114319Phase 1

Dose Finding Study of TNO155 in Adult Patients With Advanced Solid Tumors

Terminated
NCT07468071Phase 1

Rollover Study for Participants Who Have Been Treated With and Are Continuing to Benefit From Opnurasib as a Single Agent or in Combination With Other Study Treatments

Not Yet Recruiting
NCT04699188Phase 1

Study of JDQ443 in Patients With Advanced Solid Tumors Harboring the KRAS G12C Mutation

Active Not Recruiting
NCT04294160Phase 1

A Study of Select Drug Combinations in Adult Patients With Advanced/Metastatic BRAF V600 Colorectal Cancer

Terminated
NCT04185883Phase 1

Sotorasib Activity in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation (CodeBreak 101)

Active Not Recruiting
NCT04000529Phase 1

Phase Ib Study of TNO155 in Combination With Spartalizumab or Ribociclib in Selected Malignancies

Terminated
NCT04330664Phase 1

Adagrasib in Combination With TNO155 in Patients With Cancer (KRYSTAL 2)

Completed
NCT05541159Phase 1

Pharmacokinetics Study of TNO155 in Participants With Mild, Moderate, or Severe Renal Impairment Compared to Matched Healthy Participants

Withdrawn
NCT05490030Phase 1

Pharmacokinetics of TNO155 in Participants With Mild, Moderate, or Severe Hepatic Impairment Compared to Matched Healthy Participants

Withdrawn
NCT04292119Phase 1

Lorlatinib Combinations in Lung Cancer

Unknown

All 10 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
10